ArticleAsian Pacific journal of cancer prevention : APJCP2026
Standardizing Cost-Effectiveness Evidence for Cancer Prevention: A Case Study Analysis of HPV Vaccination.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer remains a leading cause of cancer mortality worldwide, with over 85% of deaths occurring in low- and middle-income countries (LMICs) where resources are scarce. A fundamental challenge in global health policy is comparing economic evaluations across these diverse settings, as traditional Incremental Cost-Effectiveness Ratios (ICERs) are constrained by different currencies, price levels, and willingness-to-pay (WTP) thresholds. To address this, we propose a standardized Cost-Effectiveness Ratio (CER), calculated as the ICER divided by the country-specific WTP threshold, creating a unitless, income-adjusted metric.
methodsWe conducted a rapid review of HPV vaccination economic evaluations published between 2022 and 2025. Employing a case study approach, we extracted original ICERs and WTP thresholds from diverse countries. All monetary values were converted to 2024 US Dollars using transparent exchange rates, with a critical handling of the Thailand WTP threshold to ensure it was based on the original Thai Baht value from the publication before conversion to USD to ensure analytical integrity. The CER was then calculated to facilitate direct comparison.
resultsThe CER provides a powerful lens for interpreting value. Our case study reveals that a vaccination strategy in China (CER=0.0002) is dramatically more favourable than one in Japan (CER=0.20), a finding obscured by absolute costs. Furthermore, the CER shows that programs in Thailand and the Philippines offer over twice the relative economic value of Japan's program. It also enables nuanced comparisons, such as between single-dose and two-dose regimens, revealing comparable value for money in lower-middle-income settings.
conclusionThe CER is a simple yet powerful tool that transforms incomparable data into a standardized metric. For international funders like Gavi and national policymakers, it provides robust evidence to prioritize investments in LMICs, where the return on investment is highest. By reframing the economic question from "can we afford it?" to "how can we afford not to?", the CER promotes health equity and strengthens the case for accelerating global HPV vaccination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.